XTL Biopharmaceuticals Ltd (XTLB) stock
XTLBNasdaqPharmaceutical Preparations
$1.64−0.02 (-1.20%)
Close on Nov 12, 2026Market cap $15.52MP/E –Yield –
XTL Biopharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
XTL Biopharmaceuticals's enterprise value was $15.63M on Nov 11, 2026, against $29.13M a year earlier. Over the last 5 years it ranged from $15.16M to $62.14M, with a median of $29.91M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $15.63M | -22.7% |
| 2025 | Dec 31, 2025 | $20.22M | -52.7% |
| 2024 | Dec 31, 2024 | $42.75M | +114.6% |
| 2023 | Dec 29, 2023 | $19.92M | -17.1% |
| 2022 | Dec 30, 2022 | $24.03M | -54.0% |
| 2021 | Dec 31, 2021 | $52.22M | -6.1% |
| 2020 | Dec 31, 2020 | $55.59M | +123.1% |
| 2019 | Dec 31, 2019 | $24.92M | -22.8% |
| 2018 | Dec 31, 2018 | $32.29M | +40.0% |
| 2017 | Dec 29, 2017 | $23.07M | -22.2% |
| 2016 | Dec 30, 2016 | $29.66M | – |
See a number that looks wrong?